( EXTON Pa.--(BUSINESS WIRE)--Apr 19 20...)Othera Pharmaceuticals Announces Upcoming Presentation Based Upon,Expanded Understanding of Lead Compound Mechanism of Action,Health

EXTON, Pa.--(BUSINESS WIRE)--Apr 19, 2007 - Othera Pharmaceuticals, Inc. today announced that Dr. Shaker Mousa, Professor of Pharmacology and Executive Vice President and Chairman of the Pharmaceutical Research Institute at Albany College of Pharmacy, will present new preclinical data detailing the observed antithrombotic effect of Othera's lead compound, OT-551, and related Othera compounds. This work stems from previous ocular studies on OT-551 eye drops, as well as studies on novel, orally-available analog compounds under development for non-ophthalmic indications. Dr. Mousa's talk will be presented at the XXI International Society on Thrombosis and Haemostasis (ISTH) Congress in Geneva, Switzerland on July 9, 2007. The ISTH holds its congress every other year and the organization includes 2,800 thrombosis, hemostasis and vascular biology researchers and clinicians from more than 70 countries.

In his abstract, Dr. Mousa describes how OT-551 operates within the cell to downregulate Nuclear Factor kappa B (NF-kB), a transcription factor whose overexpression is associated with a host of inflammation-related ocular and non-ocular diseases. In combination with OT-551's previously known antioxidant and antiangiogenic activities, elucidation of this new mechanism provides strong support for the ophthalmic indications that Othera is currently pursuing with OT-551, as well as new non-ophthalmic indications for analogous oral compounds. Specific diseases of interest to Othera that have been linked to NF-kB overactivity in the scientific literature include age-related macular degeneration (AMD), cataracts, dry eye, resistance to cancer chemotherapy, cancer-related thrombosis and rheumatoid arthritis.

A New Understanding of How OT-551 Works in Ocular Disease

In conjunction with Othera scientists, Dr. Mousa performed large-scale gene expression studies using microchip arrays that provided evidence of OT-551
'"/>

Page: 1 2 3 4
Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA